Literature DB >> 26424728

The Impact of Fractional Flow Reserve on Revascularization.

Islam Y Elgendy1, Calvin Choi1,2, Anthony A Bavry3,4.   

Abstract

INTRODUCTION: Fractional flow reserve (FFR) is recommended by society guidelines for assessment of the hemodynamic significance of intermediate coronary lesions when non-invasive evidence of myocardial ischemia is unavailable. However, the prevalence of FFR usage in current practice and how FFR values impact revascularization decisions are not well known.
METHODS: At a single-center Veterans Administration Hospital, all subjects referred for coronary angiography for any indication from the period from May 2012 until January 2014 were prospectively entered into a database. FFR was measured in all intermediate coronary lesions (30-70% stenosis). Based on the FFR results, the lesions were categorized into 3 different groups: FFR > 0.80 (non-ischemic), FFR 0.75-0.80 (gray zone), and FFR < 0.75 (ischemic).
RESULTS: A total of 1482 cardiac catheterizations were performed during the study period. FFR was performed in 347 (23%) of these procedures. The total numbers of intermediate coronary lesions evaluated with FFR were 429. The mean FFR value was 0.79 (median = 0.80; interquartile range 0.64-0.96). Among 211 non-ischemic lesions, revascularization was deferred in 201 (95%). In the gray-zone group (73 lesions), 35 (48%) lesions were treated with percutaneous coronary intervention (PCI), 11 (15%) lesions were referred for coronary artery bypass grafting surgery (CABG), and 27 (37%) lesions were treated medically. In the ischemic group (145 lesions), 82 (57%) lesions were treated with PCI, 41 (28%) lesions were referred for CABG, and 22 (15%) lesions were treated medically.
CONCLUSION: At a Veterans Administration Hospital, FFR was performed in approximately one out of four total catheterizations. FFR documented lack of ischemia in about half of the intermediate coronary lesions, and thus reduced the need for many revascularization procedures.

Entities:  

Keywords:  Coronary angiogram; Fractional flow reserve; Percutaneous coronary intervention; Revascularization

Year:  2015        PMID: 26424728      PMCID: PMC4675752          DOI: 10.1007/s40119-015-0051-1

Source DB:  PubMed          Journal:  Cardiol Ther        ISSN: 2193-6544


Introduction

Assessment of intermediate coronary lesions (30–70% stenosis) by coronary angiogram has been shown to be a poor predictor of the hemodynamic significance of the lesion [1]. Earlier studies had suggested that fractional flow reserve (FFR)-guided revascularization was superior at reducing major cardiac adverse outcomes when compared with angiogram-guided revascularization [2-4]. The 5-year follow-up of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME; Clinicaltrials.gov identifier, NCT00267774) trial demonstrated that an FFR-guided approach is associated with a similar risk of major events but with a lower number of stented arteries and less resource use [5]. FFR assessment during coronary angiography is endorsed by the European Society of Cardiology and the American College of Cardiology for identification of hemodynamically significant lesions when non-invasive evidence of myocardial ischemia is unavailable [6, 7]. Deferral of revascularization is recommended for non-ischemic lesions [8, 9]. Despite the documented benefits of FFR, some operators may not embrace the frequent use of FFR. This might be especially true in a fee-for-service system, where FFR could result in deferral of revascularization. The Veterans Health System is unique in that there is no financial incentive to perform revascularization procedures. Therefore, at a single-center Veterans Administration Hospital, our objectives were twofold. The first objective was to determine how frequently FFR was performed. The second objective was to determine how FFR values would impact the performance or deferral of revascularization, especially within the gray zone.

Methods

This was a single-center study that prospectively entered all patients referred for cardiac catheterization for any indication at the North Florida/South Georgia Veterans Health System from May 2012 until January 2014 into a database. This database was established to determine the frequency of FFR usage and how FFR values impact revascularization decisions; therefore, baseline characteristics and clinical outcomes were not recorded. Institutional Review Board approval was obtained prior to conducting the study. FFR was defined as a whole cardiac cycle pressure-derived index of the maximum achievable blood flow in a coronary artery with a stenosis expressed as a ratio of maximum achievable blood flow if that artery were normal [8, 10]. FFR was measured in all intermediate coronary lesions (30–70% stenosis) using a coronary pressure guide wire (Volcano Corporation; San Diego, CA) at maximal hyperemia induced by peripherally administrated intravenous adenosine (140 µg/kg/min for 2 min) or regadenoson (0.4 mg bolus) at operator discretion. Based on the FFR results, the lesions were categorized into three different groups: FFR > 0.80 (non-ischemic), FFR 0.75–0.80 (gray zone), and FFR < 0.75 (ischemic). The decision to defer or proceed with revascularization on the basis of FFR measurement was left to the operator’s judgment.

Results

A total of 1482 cardiac catheterizations were performed during the study period. FFR was performed in 347 (23%) of these procedures. The total numbers of intermediate coronary lesions evaluated with FFR were 429. The mean FFR value was 0.79 (median = 0.80, interquartile range 0.64–0.96). Among 211 non-ischemic lesions, revascularization was deferred in 201 (95%). In the remainder of patients with non-ischemic lesions, referral was placed for coronary artery bypass grafting surgery (CABG) for concomitant lesions in eight patients and percutaneous coronary intervention (PCI) was performed in two cases due to intravascular ultrasound findings. In the gray-zone group (73 lesions), 35 (48%) lesions were treated with PCI, 11 (15%) lesions were referred for CABG, and 27 (37%) lesions were treated medically. In the ischemic group (145 lesions), 82 (57%) lesions were treated with PCI, 41 (28%) lesions were referred for CABG, and 22 (15%) lesions were treated medically. In the gray-zone group, the most common reasons for deferring revascularization included mild angina symptoms, inadequate anti-angina therapy, or high PCI complexity. In the ischemic group, the most common reasons for deferring revascularization included small vessel size (i.e., <2.25 mm) and/or diffuse lesions that markedly increased the risk for restenosis, or high PCI complexity. Figure 1 summarizes the percentage of lesions in each group.
Fig. 1

Summary for the percentage of lesions in each group. a Percentage of lesions in each fractional flow reserve category. Distribution of treatment (medical, revascularization, or referral for CABG) in the non-ischemic group (b), gray-zone group (c), and ischemic group (d). CABG coronary artery bypass grafting surgery, PCI percutaneous coronary intervention

Summary for the percentage of lesions in each group. a Percentage of lesions in each fractional flow reserve category. Distribution of treatment (medical, revascularization, or referral for CABG) in the non-ischemic group (b), gray-zone group (c), and ischemic group (d). CABG coronary artery bypass grafting surgery, PCI percutaneous coronary intervention

Discussion

In the United States, the average use of FFR has been reported to be as low as 6.1%, with more FFR procedures performed in academic institutions, particularly those with fellowship programs [11]. FFR usage is affected by operator expertise, reimbursement, and the availability of necessary equipment. At our institution, FFR was performed at a higher rate than previously reported; however, as previously mentioned, the Veterans Health System is unique since there is no financial incentive to perform revascularization procedures. Incorporating FFR in revascularization decisions has been demonstrated to result in fewer PCI procedures [2, 12–14]. Our results showed that FFR usage resulted in deferral of revascularization in approximately half of the cases due to non-ischemic lesions. In the gray-zone group, approximately 63% of the lesions either underwent PCI or referred for CABG, which is slightly higher than prior studies [15, 16]. Recent studies had suggested increasing the sensitivity for detecting ischemia (i.e., the threshold for revascularization changed from FFR < 0.75 to <0.80) [4]. We observed that 37% of gray-zone lesions were deferred revascularization which illustrates that in real-life clinical practice there is still adequate room for medical management and clinical judgment for such lesions. In other words, an FFR value <0.80 should not be an ‘automatic license’ to perform revascularization. Revascularization was deferred in the gray-zone group mostly due to mild symptoms and/or inadequate anti-angina therapy. In the ischemic group, revascularization was deferred infrequently (15%). This was mostly due to anatomical concerns (characteristics that made PCI high risk or significantly increased the risk for restenosis). This study was limited by being an observational study conducted in a single academic center. We did not report any baseline characteristics or clinical outcome data; however, this information would not be considered particularly germane to the stated objectives of this study. Moreover, this information can be found in other reports. Meta-analysis of observational studies has documented similar outcomes associated with deferral of non-ischemic left main lesions compared with revascularization of ischemic left main lesions. On the other hand, adverse outcomes are low with deferral of non-ischemic lesions compared with revascularization of ischemic lesions for non-left main lesions [9].

Conclusions

In a single-center practice that does not provide a financial incentive for performing revascularization procedures, FFR usage occurred at a higher frequency than previously reported (approximately one in four catheterization procedures). Frequent use of FFR documented lack of ischemia in about half of the intermediate coronary lesions, and thus reduced the need for many revascularization procedures. Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 199 kb)
  15 in total

1.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

Authors:  Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting
Journal:  J Am Coll Cardiol       Date:  2011-11-07       Impact factor: 24.094

2.  Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study.

Authors:  Nico H J Pijls; Pepijn van Schaardenburgh; Ganesh Manoharan; Eric Boersma; Jan-Willem Bech; Marcel van't Veer; Frits Bär; Jan Hoorntje; Jacques Koolen; William Wijns; Bernard de Bruyne
Journal:  J Am Coll Cardiol       Date:  2007-05-17       Impact factor: 24.094

3.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Authors:  Gilles Montalescot; Udo Sechtem; Stephan Achenbach; Felicita Andreotti; Chris Arden; Andrzej Budaj; Raffaele Bugiardini; Filippo Crea; Thomas Cuisset; Carlo Di Mario; J Rafael Ferreira; Bernard J Gersh; Anselm K Gitt; Jean-Sebastien Hulot; Nikolaus Marx; Lionel H Opie; Matthias Pfisterer; Eva Prescott; Frank Ruschitzka; Manel Sabaté; Roxy Senior; David Paul Taggart; Ernst E van der Wall; Christiaan J M Vrints; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Juhani Knuuti; Marco Valgimigli; Héctor Bueno; Marc J Claeys; Norbert Donner-Banzhoff; Cetin Erol; Herbert Frank; Christian Funck-Brentano; Oliver Gaemperli; José R Gonzalez-Juanatey; Michalis Hamilos; David Hasdai; Steen Husted; Stefan K James; Kari Kervinen; Philippe Kolh; Steen Dalby Kristensen; Patrizio Lancellotti; Aldo Pietro Maggioni; Massimo F Piepoli; Axel R Pries; Francesco Romeo; Lars Rydén; Maarten L Simoons; Per Anton Sirnes; Ph Gabriel Steg; Adam Timmis; William Wijns; Stephan Windecker; Aylin Yildirir; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

4.  Contemporary patterns of fractional flow reserve and intravascular ultrasound use among patients undergoing percutaneous coronary intervention in the United States: insights from the National Cardiovascular Data Registry.

Authors:  Philip B Dattilo; Anand Prasad; Emily Honeycutt; Tracy Y Wang; John C Messenger
Journal:  J Am Coll Cardiol       Date:  2012-12-04       Impact factor: 24.094

5.  Outcomes associated with fractional flow-guided revascularization: a meta-analysis.

Authors:  Anthony A Bavry; Islam Y Elgendy; John W Petersen
Journal:  Clin Cardiol       Date:  2014-07-18       Impact factor: 2.882

6.  Clinical outcome following conservative vs revascularization therapy in patients with stable coronary artery disease and borderline fractional flow reserve measurements.

Authors:  Michael Lindstaedt; Yasemin Halilcavusogullari; Aydan Yazar; Tim Holland-Letz; Waldemar Bojara; Andreas Mügge; Alfried Germing
Journal:  Clin Cardiol       Date:  2010-02       Impact factor: 2.882

Review 7.  Fractional flow reserve: an updated review.

Authors:  Islam Y Elgendy; C Richard Conti; Anthony A Bavry
Journal:  Clin Cardiol       Date:  2014-03-20       Impact factor: 2.882

8.  Fractional flow reserve-guided PCI for stable coronary artery disease.

Authors:  Bernard De Bruyne; William F Fearon; Nico H J Pijls; Emanuele Barbato; Pim Tonino; Zsolt Piroth; Nikola Jagic; Sven Mobius-Winckler; Gilles Rioufol; Nils Witt; Petr Kala; Philip MacCarthy; Thomas Engström; Keith Oldroyd; Kreton Mavromatis; Ganesh Manoharan; Peter Verlee; Ole Frobert; Nick Curzen; Jane B Johnson; Andreas Limacher; Eveline Nüesch; Peter Jüni
Journal:  N Engl J Med       Date:  2014-09-01       Impact factor: 91.245

9.  Comparison of medical treatment and coronary revascularization in patients with moderate coronary lesions and borderline fractional flow reserve measurements.

Authors:  Javier Courtis; Josep Rodés-Cabau; Eric Larose; Jean-Pierre Déry; Can Manh Nguyen; Guy Proulx; Onil Gleeton; Louis Roy; Gerald Barbeau; Bernard Noël; Robert DeLarochellière; Olivier F Bertrand
Journal:  Catheter Cardiovasc Interv       Date:  2008-03-01       Impact factor: 2.692

10.  Long-term survival in patients undergoing percutaneous interventions with or without intracoronary pressure wire guidance or intracoronary ultrasonographic imaging: a large cohort study.

Authors:  Georg M Fröhlich; Simon Redwood; Roby Rakhit; Philip A MacCarthy; Pitt Lim; Tom Crake; Steven K White; Charles J Knight; Christoph Kustosz; Guido Knapp; Miles C Dalby; Iqbal S Mali; Andrew Archbold; Andrew Wragg; Adam D Timmis; Pascal Meier
Journal:  JAMA Intern Med       Date:  2014-08       Impact factor: 21.873

View more
  3 in total

Review 1.  Clinical Application of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention for Stable Coronary Artery Disease.

Authors:  Valay Parikh; Kanishk Agnihotri; Sabeeda Kadavath; Nileshkumar J Patel; J Dawn Abbott
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

2.  Preliminary Report on the Safety and Efficacy of Staged versus Complete Revascularization in Patients with Multivessel Disease at the Time of Primary Percutaneous Coronary Intervention.

Authors:  Marwan Saad; Ahmed Rashed; Wael El-Kilany; Mohamed El-Haddad; Islam Y Elgendy
Journal:  Int J Angiol       Date:  2016-02-18

3.  Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study).

Authors:  Anthony A Bavry; Ki E Park; Calvin Y Choi; Ahmed N Mahmoud; Xuerong Wen; Islam Y Elgendy
Journal:  Cardiol Ther       Date:  2017-01-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.